Shorter treatment for rifampicin-resistant TB sensitive to isoniazid
Part of Infections, Lungs & breathing clinical trials.
This trial tests a shorter treatment for TB that is resistant to the drug rifampicin but still sensitive to isoniazid. It may help people finish treatment sooner and with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have tuberculosis (TB) in your lungs, confirmed by a lab test.
- Your TB bacteria are resistant to the drug rifampicin but still sensitive to isoniazid (or you can't take rifampicin/rifabutin for medical reasons).
- Your TB bacteria are sensitive to a class of antibiotics called fluoroquinolones.
- You are willing to come to the clinic for follow-up visits and take your medications as directed.
- If you are a woman of childbearing age, you agree to use effective birth control during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether you can take a shorter course of standard treatment for drug-sensitive pulmonary (lung) tuberculosis by using a higher dose of rifampicin. It may help some people finish treatment sooner, while doctors track how well the infection clears.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This trial tests whether a shorter, rifampicin-based treatment works well for people with less severe TB in the lungs. If you have limited TB that is sensitive to rifampicin, you might be able to take medicine for a shorter time than usual.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.